Moderna partners with pharmaceutical firm for vaccine application, distribution

US vaccine maker Moderna has partnered with Asian pharmaceutical distributor Zuellig Pharma Corp. in its application for emergency use authorization (EUA) in the Philippines and the distribution of its coronavirus disease 2019 (Covid-19) vaccine in Asian countries.

In a statement, Zuellig, through its commercial division ZP Therapeutics, applied the EUA of Moderna’s mRNA-1273 vaccine with the Philippine Food and Drug Administration (FDA) on Monday.

Moderna has appointed ZP Therapeutics as its EUA holder and distributor for the vaccine in the country.

Raymund Azurin, Senior Vice President for Government Affairs and Sustainability of Zuellig Pharma, said that it looks forward to the decision of the FDA after it filed its application with all the required documents.

“We welcome this partnership with Moderna to bring their mRNA-based Covid-19 vaccine and its potential benefits to the Philippines and the rest of the Asia region.” Azurin added.

John Graham, Chief Executive of Zuellig Pharma, said that their collaboration with Moderna to supply the vaccine in Asia reaffirms the company’s commitment in fighting Covid-19.

“We are committed to making healthcare accessible through innovation, commercial excellence and robust in-market capabilities that will not only improve healthcare but will expand patient access” Graham added.

Vaccine Czar Secretary Carlito Galvez, Jr. has welcomed the EUA application of Moderna, saying that it will allow the country to reach its goal of vaccinating 70 million adult Filipinos this year.

Corinne Le Goff, Chief Commercial Officer of Moderna, said that their collaboration with partners will ensure the successful delivery of the vaccine in the market.

The Philippines expects around 20 million doses of the Moderna vaccine to arrive starting in May, with 13 million allotted to the government and the rest to the private sector.